Literature DB >> 17337137

Nasal administration of an angiotensin antagonist in the rat model: effect of bioadhesive formulations on the distribution of drugs to the systemic and central nervous systems.

S T Charlton1, S S Davis, L Illum.   

Abstract

The effect of bioadhesive formulations on the direct transport of an angiotensin antagonist drug ((14)C-GR138950) from the nasal cavity to the central nervous system was evaluated in a rat model. Three different bioadhesive polymer formulations (3% pectin LM-5, 1.0% pectin LM-12 and 0.5% chitosan G210) containing the drug were administered nasally to rats by inserting a dosing cannula 7mm into the nasal cavity after which the plasma and brain tissue levels were measured. It was found that the polymer formulations provided significantly higher plasma levels and significantly lower brain tissue levels of drug than a control, in the form of a simple drug solution. Changing the depth of insertion of the cannula from 7 to 15mm, in order to reach the olfactory region in the nasal cavity significantly decreased plasma levels and significantly increased brain tissue levels of drug for the two formulations studied (1.0% pectin LM-12 and a simple drug solution). There was no significant difference between the drug availability for the bioadhesive formulation and the control in the brain when the longer cannula was used for administration. It is suggested that the conventional rat model is not suitable for evaluation of the effects of bioadhesive formulations in nose-to-brain delivery.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17337137     DOI: 10.1016/j.ijpharm.2007.01.047

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  7 in total

1.  Effects of localized hydrophilic mannitol and hydrophobic nelfinavir administration targeted to olfactory epithelium on brain distribution.

Authors:  John Douglas Hoekman; Rodney J Y Ho
Journal:  AAPS PharmSciTech       Date:  2011-04-26       Impact factor: 3.246

2.  Pharmacokinetic comparison between the long-term anesthetized, short-term anesthetized and conscious rat models in nasal drug delivery.

Authors:  Yin Cheong Wong; Shuai Qian; Zhong Zuo
Journal:  Pharm Res       Date:  2014-02-20       Impact factor: 4.200

3.  Intranasal delivery of N-terminal modified leptin-pluronic conjugate for treatment of obesity.

Authors:  Dongfen Yuan; Xiang Yi; Yuling Zhao; Chi-Duen Poon; Kristin M Bullock; Kim M Hansen; Therese S Salameh; Susan A Farr; William A Banks; Alexander V Kabanov
Journal:  J Control Release       Date:  2017-03-24       Impact factor: 9.776

4.  Evaluation of direct transport pathways of glycine receptor antagonists and an angiotensin antagonist from the nasal cavity to the central nervous system in the rat model.

Authors:  Stuart T Charlton; Joanne Whetstone; Susan T Fayinka; Kevin D Read; Lisbeth Illum; Stanley S Davis
Journal:  Pharm Res       Date:  2008-02-22       Impact factor: 4.200

Review 5.  Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies.

Authors:  Gina Li; Nicolas Bonamici; Mahua Dey; Maciej S Lesniak; Irina V Balyasnikova
Journal:  Expert Opin Drug Deliv       Date:  2017-09-18       Impact factor: 6.648

6.  Low-dose oxytocin delivered intranasally with Breath Powered device affects social-cognitive behavior: a randomized four-way crossover trial with nasal cavity dimension assessment.

Authors:  D S Quintana; L T Westlye; Ø G Rustan; N Tesli; C L Poppy; H Smevik; M Tesli; M Røine; R A Mahmoud; K T Smerud; P G Djupesland; O A Andreassen
Journal:  Transl Psychiatry       Date:  2015-07-14       Impact factor: 6.222

7.  Intranasal administration of oxytocin: behavioral and clinical effects, a review.

Authors:  Jan G Veening; Berend Olivier
Journal:  Neurosci Biobehav Rev       Date:  2013-05-04       Impact factor: 8.989

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.